Table 4.
Correlation between CTC alterations and clinicopathological features of the melanoma patients.
| Clinicopathological features | Patient # of decreased or unchanged CTC | Patient # of increased CTC | P value | |
|---|---|---|---|---|
| Age | <45 (%) | 33 (49.3) | 17 (51.5) | 0.832 |
| ≥45 (%) | 34 (50.7) | 16 (32) | ||
| Gender | Female (%) | 24 (42.1) | 14 (32.6) | 0.330 |
| Male (%) | 33 (57.8) | 29 (67.4) | ||
| Histology type | ALM (%) | 47 (70.1) | 25 (75.8) | 0.557 |
| Other (%) | 20 (29.9) | 8 (24.2) | ||
| S100B (μg/L) | <0.19 (%) | 31 (46.3) | 19 (57.8) | 0.288 |
| ≥0.19 (%) | 36 (53.7) | 14 (42.4) | ||
| Breslow thickness (mm) | <2.0 (%) | 38 (56.7) | 23 (69.7) | 0.211 |
| ≥2.0 (%) | 29 (43.3) | 10 (30.3) | ||
| Ulceration | No (%) | 45 (67.2) | 18 (54.5) | 0.219 |
| Yes (%) | 22 (32.8) | 15 (45.5) | ||
| N stage | N0/Nx (%) | 45 (67.2) | 26 (78.8) | 0.228 |
| N1+ (%) | 22 (32.8) | 7 (21.3) | ||
| M stage | No (%) | 38 (56.7) | 16 (48.5) | 0.437 |
| Yes (%) | 29 (43.3) | 17 (51.5) | ||
| TNM stage | I–II (%) | 36 (53.7) | 17 (51.5) | 0.835 |
| III–IV (%) | 31 (46.3) | 16 (48.5) | ||
| Outcome | Survived (%) | 22 (32.8) | 9 (27.3) | 0.572 |
| Died (%) | 45 (67.2) | 24 (72.7) | ||
ALM – acral lentiginous meloanoma.